~" The results of transsphenoidal adenomectomy for growth hormone (GH)-secreting pituitary adenomas in acromegaly performed over a 17-year period were analyzed retrospectively to determine which preoperative factors significantly influenced the long-term surgical outcome. These variables were then used to develop a logistic regression model to determine the probability of surgical failure.
S

INCE Cushing 17 first performed a transsphenoidal
operation in 1909 to treat a patient with acromegaly, there have been many reports of successful treatment of growth hormone (GH)-secreting pituitary adenomas with transsphenoidal adenomectomy. 2'6' 10,23,25,28,3o,34,35,37,54,57,6o ,61 Interestingly, irradiation, an alternative therapy, was also first applied in 1909.12 '24 Transsphenoidal microsurgical adenomectomy has since become the preferred treatment for GH-secreting pituitary adenomas. The surgical outcome is successful in about 85% of patients with noninvasive microadenomas and a preoperative serum GH level of less than 40 #g/liter. 35"48' 5~ The definition of surgical success in controlling acromegaly varies among authors. Some accept a postoperative reduction in serum basal GH levels to below 10 #g/liter, ~~ while others prefer a level under 5 #g/ liter. 3 
"6"14~25"41' 5~
A few consider the results of GH responses to dynamic testing. 4 
"2~
Since 1973, we have used a level of 5 ug/liter as our postoperative GH criterion for surgical success. However, single measurements of GH are of limited value because GH secretion fluctuates 55 and GH levels below 5 gg/liter occur in patients with active acromegaly. ~9.5~ One study suggested that a postoperative serum basal GH level below 3 gg/liter is better related to the restoration of normal GH response. 65 Although the level of somatomedin C (SM-C) is less apt to fluctuate and SM-C studies could replace the more extensive testing needed with GH levels, few surgical series have used the postoperative SM-C level as a measure of surgical success. 3,36, 45A6 The criteria for the strict biochemical cure of acromegaly are more exacting than the postoperative serum basal levels of GH used in most surgical series. These criteria are the reduction of GH levels to less than 2 ug/liter after the ingestion of 75 gm glucose, a normal circadian rhythm of GH secretion, and an appropriate GH response to provocative stimuli such as thyrotropin-releasing hormone. We agree with others that partial satisfaction of these criteria should be designated as control, as opposed to cure, of acromegaly, l'> Despite normalization of GH levels and dynamic GH responses, acromegaly may recur years after surgery. ~3' -s~ Given these observations and the paucity of long-term follow-up data in many surgical series, we sought to determine which preoperative factors significantly influenced the long-term surgical outcome of patients with GH-secreting pituitary, adenomas. We applied these factors to develop a logistic regression model for determining the probability of surgical failure. Our criteria for surgical control at long-term followup evaluation were a postoperative serum basal GH level below 5 ug/liter, a postoperative serum SM-C level below 2.2 U/ml, and the absence of clinical evidence of persistently elevated GH secretion.
In an earlier report, 57 we had examined our longterm results in 50 patients. In the current publication, we extend these observations after a more stringent analysis of 103 patients followed for a longer duration.
Clinical Material and Methods
Between August, 1973, and May, 1990, 103 patients with GH-secreting pituitary adenomas and acromegaly were treated by the neurosurgical service at Emory University Affiliated Hospitals. We retrospectively analyzed these patients' charts and reports from referring physicians, primarily endocrinologists. More current data were derived from follow-up telephone conversations with patients and physicians. Our database included clinical evaluation, preoperative hormonal indices, neuroradiological and operative findings, and the results of surgery, such as the extent of tumor removal, postoperative hormonal indices, clinical outcome, and complications.
Acromegaly was defined biochemically as a preoperative serum basal GH level above 10 #g/liter, the failure of GH suppression after an oral glucose load, an elevated level of SM-C (insulin-like growth factor I) (> 1.9 U/ml in men and > 2.2 U/ml in women), and by the classic clinical features of acral enlargement. Because of the wide clinical expression of this disease, we focused on the classic features of acromegaly and certain commonly associated conditions, such as hypertension, visual changes, amenorrhea/galactorrhea, osteoarthritis, carpal tunnel syndrome, diabetes mellitus, and other endocrinopathies.
Patient Population
There were 55 females and 48 males, ranging in age from 9 to 72 years (mean 45.3 + 12.7 years). There was no significant age difference between the men (mean age 44.9 _+ 11.1 years) and the women (mean age 45.8 _+ 13.9 years). These characteristics are consistent with the mean age at diagnosis in patients with acromegaly (40 years for men and 45 years for women) and the equal incidence of the disease in both sexes. 1"4~ All patients had clinical features of acromegaly except for one girl, aged 9 years, with gigantism. Of the 55 females, five (9%) suffered amenorrhea/galactorrhea; 10 (18%) diabetes mellitus; 16 (29%) visual deficits; six (11%) hypertension; five (9%) osteoarthritis; and four (7%) carpal tunnel syndrome, with one case being bilateral. Of the 48 males, six (12%) presented with diabetes mellitus; 11 (23%) with visual deficits; five (10%) with preoperative anterior pituitary lobe dysfunction; four (8%) with hypertension; two (4%) with carpal tunnel syndrome; six (12%) with osteoarthritis; and one (2%) with pituitary apoplexy.
The period of follow-up monitoring ranged from 4 to 219 months (mean 102 + 64 months). Five patients died and 10 patients were lost to follow-up study during the period under study. Forty-three patients (42%) were followed for 10 years or more, 52 (50%) for 8 to 10 years, and 70 (68%) for 5 to 8 years.
Previous Treatment
Two patients had been treated elsewhere by craniotomy alone, and 11 patients had received radiotherapy elsewhere before undergoing transsphenoidal microsurgery at our institution. Our surgical treatment generally addressed inadequate response to radiotherapy. For example, one patient had previously received conventional radiotherapy and then experienced increasing GH levels 4 years after treatment; another patient was referred for surgery because of worsening clinical symptoms 6 years after undergoing radiotherapy. A third patient's clinical condition had not improved significantly 8 years following radiotherapy, and in a fourth patient tumor recurred 13 years after radiotherapy, which prompted referral. A fifth patient had been treated elsewhere with craniotomy and then radiotherapy; however, the tumor continued to enlarge and the GH levels steadily increased.
Four patients had received preoperative bromocriptine therapy. Two patients were treated for 6 months elsewhere; the therapy was discontinued by one patient due to side effects and by the other because he did not consider the drug helpful. Two other patients treated elsewhere were referred for inadequate medical response.
Preoperative Evaluation
Growth Hormone Level. The human serum GH level was determined by competitive binding radioimmunoassay.* Analytical variation of the assay was less than 8%. The normal basal value for serum GH is at or below 10 #g/liter. Preoperative basal GH levels were available for all 103 patients and ranged from 1.0 to 161 ug/liter (mean 41.5 + 37.1 ug/liter). One patient with pituitary apoplexy had a GH level of less than 1 ug/liter. Fourteen patients with clinical acromegaly had normal (_< I0 ug/liter) preoperative serum basal GH levels, with three between 9 and 10 gg/liter, six between 6 and 8 •g/liter, and five between 2 and 6 gg/liter. All of these 14 patients had radiological evidence of pituitary adenoma, which was confirmed at surgery. Five of the 14 patients with normal preoperative serum basal GH levels had elevated SM-C levels and one had a normal SM-C level; the SM-C levels in eight of these patients were not available.
The GH level was not suppressed after oral glucose intake (75 to 100 gm) in all 80 patients for whom such information was available. The GH response to thyrotropin-releasing hormone stimulation was available for five patients, and the response was paradoxical (increased GH level after thyrotropin-releasing hormone stimulation) in all. Preoperative serum GH was a univariate predictor of surgical outcome in the logistic regression model.
Somatomedin C Level. The SM-C level was measured by competitive binding radioimmunoassay. Analytical variation of the assay was less than 10%. The normal value for SM-C in women aged 18 to 64 years ranges from 0.45 to 2.2 U/ml and in men in a similar age group from 0.34 to 1.9 U/ml. Preoperative SM-C values were available for 32 patients and ranged from 0.57 to 17.9 U/ml (mean 5.3 + 4.2 U/ml). Preoperative SM-C correlated significantly with preoperative GH (r = 0.45, p = 0.009). This relationship is not surprising since the peripheral effect of GH is mediated in part through somatomedinsr 2 Plasma SM-C is uniformly elevated in acromegalic patients with active disease ~'4~ and, since plasma SM-C has a long half-life, it reflects the integrative activity of bioactive GH levels over several days. Thus, plasma SM-C is a more reliable index of GH activity than single basal serum levels of GH. The correlation we observed between preoperative and short-term postoperative SM-C levels in 19 patients (r = 0.52, p = 0.2) also suggests that preoperative SM-C is a reliable indicator of postoperative SM-C level, at least in the short term. Prolactin Level. In our laboratory, the normal serum prolactin level in men is 2 to 12 ug/liter and in premenopausal women 2 to 20 ug/liter. Prolactin was measured by an immunometric assay;? the interassay and intra-assay coefficients of variation ranged from 3.7 to 4.3 and 5.8 to 6.0, respectively. Preoperative prolactin values were available for 67 patients and ranged from 1 to 345 ug/liter (mean 37.5 _+ 53.0 ug/ liter) The closest correlation between preoperative prolactin and other preoperative hormone levels was with preoperative GH (r = 0.23, p = 0.059).
The association between prolactin and other hormones in acromegaly is complex. Hyperprolactinemia has been reported in 25% to 40% of patients with acromegaly 2' and may be due to the stalk effect or dual hormone-secreting tumors such as mixed or acid stemcell adenomas. Prolactin has growth-promoting activity, z2 and elevated prolactin levels can maintain normal to high levels of SM-C in patients with pituitary tumors and GH deficiencyJ 5 Thus, it was important to explore the relationship between prolactin and other hormone t Immunometric analyzer, Model A 1A 1200, manufactured by Tosoh Medics, Inc., San Francisco, California. levels in our patients. Interestingly, some authors have reported no correlation between prolactin and GH levels in patients with acromegaly. 6 Radiological Evaluation. Radiological evaluation of the patients in this series reflects the evolution in imaging techniques. Early in the series, some patients were studied by pneumoencephalography and cerebral arteriography. Recently, magnetic resonance imaging has replaced computerized tomography as the study of choice. Skull x-ray films were obtained in all patients to determine the degree of pneumatization of the sphenoid sinus. Information obtained from these studies was used for operative planning and tumor classification.
Tumor Classification
Tumors were categorized by stage and grade according to modified Hardy classification based on radiological and intraoperative findings. . All tumor specimens were studied by routine histological methods and most by immunoperoxidase staining for the presence of GH and prolactin; a few specimens were studied by electron microscopy.
Surgery
All patients underwent transsphenoidal microsurgical adenomectomy via a unilateral transseptal approach. 56 Surgery was not the primary treatment in all patients; 15 patients were referred for surgery after unsuccessful treatment with bromocriptine or radiation therapy. The surgeon made every reasonable attempt to achieve a gross total tumor resection while preserving the normal gland. A satisfactory assessment of the extent of surgical resection was made in 102 patients; of these, subtotal resections were performed in eight (7.8%) and gross total resection was achieved in 91 (89.2%). Hypophysectomy was performed in three patients (2.9%); two patients did not respond adequately to an initial transsphenoidal adenomectomy at our institution and one patient had undergone a craniotomy elsewhere.
Patients were monitored in the neurosurgical intensive care unit for 24 hours after surgery and were usually ambulatory by the next day. Tapering doses of hydrocortisone were given perioperatively, and a serum cortisol level was obtained in the morning before discharge. Patients were started on replacement therapy as needed. 
Postoperative Evaluation
Postoperative assessment included clinical evaluation and endocrinological and radiological studies when indicated. The GH and SM-C levels were tested within 6 months of surgery and then at regular intervals thereafter, usually annually or more frequently if indicated.
Statistical A natysis
Numerical data are expressed as the mean _-2-standard error of the mean. Analyses included Student's t-test, chi-squared test, and analysis of variance, using the SAS statistical package.:~ The association between variables was examined with correlation coefficients (Spearman or Pearson) and regression analysis. A p value of less than 0.05 was considered significant. Outcome predictions were determined by univariate and multivariate logistic regression modeling.
Regression analysis is a statistical method that examines the relationship between a response variable (in this case the surgical outcome) and one or more explanatory variables (preoperative GH level, SM-C level, and tumor stage and grade). The logistic regression model that determines discrete outcomes (taking on two or more possible values) has become the standard method of analysis in these situations, z7 We sought to estimate the probability of transsphenoidal microsurgical treatment failure in patients with acromegaly.
In the univariate analysis, we explored the possibility that one explanatory variable, such as postoperative GH or SM-C level, could predict the specific criteria of success or overall surgical outcome (hormone values and clinical outcome). In the multivariate analysis, we used all variables that were significant or relevant to develop each of our models. Many preoperative variables influence outcome. Therefore, the multivariate analysis is a more useful modei for predicting surgical outcome.
SAS statistical package developed by SAS Institute, Inc., Cary, North Carolina.
Results
Transsphenoidal surgery for acromegaly in patients treated previously with radiotherapy or bromocriptine administration is associated with a lower rate of success. ~'j~ In this series, 82.4% of previously untreated patients experienced control of their acromegaly by transsphenoidal surgery, compared with 75% of patients with prior bromocriptine treatment and 63.6% of patients who had received radiotherapy before. Preoperative GH, SM-C, and prolactin levels were lower in patients who had received preoperative treatment than in untreated patients. Although our sample size in these subsets precludes a valid statistical analysis, our findings nevertheless parallel those of others. 5'1~ Table 1 shows the breakdown of the series according to preoperative treatment and pre-and postoperative endocrinological indices.
Tumor Classification
A satisfactory assessment of tumor stage was made in 84 patients ( Table 2 Table  2 shows the breakdown of our series according to tumor stage. A satisfactory assessment of tumor grade was made in 84 patients (Table 3) . A majority of patients, 45 (53.6%), harbored macroadenomas (_> 10 mm or Grade 2 tumors). Grade 3 tumors were associated with the highest mean preoperative levels of SM-C (8.3 _+ 5.6 U/ml) and prolactin (45.2 _+ 78.1 ug/liter). Two patients with Grade 4 tumors had the highest mean preoperative serum basal GH level (73.7 ug/liter). There were no patients with Grade 5 tumors.
The surgical control rates in patients with Grade 1 and 2 tumors were 11 (73.3%) of 15 and 39 (86.7%) of 45 patients, respectively. This rate decreased to 15 (68.2%) of 22 in patients with Grade 3 tumors. Neither patient with a Grade 4 tumor experienced control of their acromegaly with surgery alone. Table 3 shows the breakdown of our series according to tumor grade.
Postoperative Growth Hormone Level
Short-Term Study. Serum basal GH levels obtained at 1 to 6 months following surgery were available in 89 patients. The levels ranged from 0.6 to 55 ug/liter (mean 5.3 _ 9.9 ug/liter). Since 72 of 89 patients had GH levels at or below 5 ug/liter, the short-term surgical control rate (measured by the GH criterion) was 80.9 %. Persistently elevated GH values (>__ 10 ug/liter) were found in 10 patients (1 1.2%).
The short-term postoperative serum basal GH levels correlated significantly with the preoperative basal GH level (r = 0.32, p = 0.001, 89 cases), the long-term postoperative GH level (r = 0.63, p = 0.0001, 78 cases), the short-term postoperative SM-C level (r = 0.53, p = 0.007, 24 cases), and the long-term postoperative SM-C level (r = 0.4, p = 0.02, 38 cases). None of these variables emerged as a significant univariate predictor of short-term postoperative GH below 5 ug/liter when analyzed by logistic regression analysis (p < 0.05). Preoperative GH was the best determinant, albeit with a p value of 0.08.
Long-Term Study. Serum basal GH levels obtained at or after 12 months following surgery were available in 91 patients. Since 86% of the patients were followed for longer than 24 months, the most recent GH value was used for long-term analysis. These values ranged from 0.16 to 48 #g/liter (mean 5.1 _ 7.7 #g/liter); 74 of 91 patients had GH levels at or below 5 ug/liter, resulting in a long-term surgical control rate, judging by the GH criterion, of 81.3%. Persistently elevated GH values (_> 10 ug/liter) were found in 11 patients (12.1%); therefore, these cases were considered failures of surgical treatment.
The long-term postoperative serum basal GH levels t Two patients with Grade 1 tumors and one patient with a Grade 2 tumor had inadequate data to classify their outcome.
correlated significantly with the short-term postoperative basal GH level (r = 0.6, p = 0.0001, 78 cases) and the long-term postoperative SM-C level (r = 0.5, p = 0.0008, 81 cases). However, the preoperative basal GH level was not significantly correlated (r = 0.2, p = 0.056, 91 cases) with the long-term postoperative GH level.
To determine if preoperative hormone levels could significantly predict one criterion of outcome (in this case a long-term postoperative GH level below 5 ug/ liter), we applied logistic regression analysis to our data. Despite the correlations noted above, none of those variables were significant univariate predictors of a long-term postoperative GH level below 5 ug/liter (p < 0.05). The preoperative SM-C level was the best univariate determinant of this criterion (p = 0.07). Although univariate analysis did not yield significant regressors for long-term GH level, multivariate analysis allowed us to build a reliable regression model for predicting surgical outcome, which is determined by clinical evaluation as well as postoperative hormonal levels.
Postoperative Somatomedin C Level Short-Term Study. Serum basal SM-C levels obtained at 6 months postoperatively or sooner were available in 25 patients and ranged from 0.45 to 10.74 U/ml (mean 2.6 _+ 3.13 U/ml). In 19 patients (76%) these SM-C values were 2.2 U/ml or below; thus, the short-term control rate by the SM-C criterion was 76%. Six patients (24 %) had persistently elevated SM-C levels (> 2.2 U/ml) at short-term follow-up examination. Short-term postoperative SM-C levels and preoperarive serum basal GH levels were marginally correlated (r = 0.4, p = 0.054, 25 cases). The short-term postoperative SM-C level correlated significantly with the short-term postoperative basal GH levels (r = 0.53, p = 0.007, 24 cases). A similar relationship between shortterm postoperative SM-C and short-term postoperative basal GH has been reportedr As determined by logistic regression analysis, the preoperative SM-C level was the only significant univariate predictor of a short-term postoperative SM-C level below 2.2 U/ml (p = 0.04).
Long-Term Study. Serum basal SM-C levels were available in the long-term (_> 12 months) postoperative period in 42 patients. Since 86% of the patients were followed for longer than 24 months, the most recent SM-C value was used for long-term analysis. These values ranged from 0.16 to 12 U/ml (mean 2.1 _+ 2.52 U/ml) and were at or below 2.2 U/ml in 32 patients. Thus, the long-term control rate by the SM-C criterion was 76.2 %, which is consistent with our short-term SM-C control rate of 76%. Persistently elevated SM-C levels (> 2.2 U/ml) were found in 10 patients (23.8%); these cases were considered failures of surgical treatment. Long-term postoperative SM-C levels were significantly correlated with the short-term postoperative basal GH level (r = 0.4, p --0.02, 38 cases) and the long-term postoperative basal GH level (r = 0.5, p = 0.0008, 41 cases). Similar relationships between the postoperative GH and SM-C levels have been reported. 36 This underscores the utility of the SM-C level for postoperative monitoring in acromegaly. Significant predictors of a long-term postoperative SM-C level below 2.2 U/ml were determined by logistic regression analysis of the preoperative variables. Tumor grade was the only significant univariate predictor (p = 0.04). Preoperative SM-C (p = 0.08) and GH (p = 0.2) levels were not statistically significant univariate predictors.
Postoperative Prolactin Level
Postoperative prolactin levels were available in 57 patients and ranged from 1 to 76 ug/liter (mean 10.5 _+ 12.3 ug/liter). Most patients achieved a reduction in preoperative prolactin levels. This is consistent with the expectation that normal pulsatile prolactin secretion may resume after successful surgical treatment of acromegaly. 44 
Surgical Outcome
Extent of Resection. Of the eight patients who had subtotal resections, only one (12.5%) fulfilled the criteria for surgical control. Conversely, gross total resection resulted in a higher surgical control rate; of 91 patients who had gross total resections, 79 (86.8%) fulfilled the criteria for surgical control. Ten patients (11%) who were presumed to have had gross total resection had recurrence of acromegaly after long-term follow-up examination. Clearly, the resectability of a tumor depends on its surgical accessibility; therefore, these apparent differences in outcome most likely reflect the tumor stage and grade.
Complications. There were no operative deaths. Surgical morbidity included one case of CSF leak that required surgical repair, four cases of temporary CSF leak, and two cases of prolonged (_ 1 year) intermittent CSF leak that did not require surgery. Three patients (2.9%) developed partial or complete anterior lobe dysfunction and three others (2.9%) developed panhypopituitarism. Temporary diabetes insipidus occurred in seven patients (6.8%); there was one case of permanent diabetes insipidus. One patient suffered permanent progressive visual loss and had memory difficulties and absence seizures following surgery.
Outcome Prediction
To determine whether and to what extent the preoperative variables (GH level, SM-C level, tumor stage and grade) influenced the outcome of transsphenoidal surgery, we subjected our data to logistic regression analysis. From this, we determined that tumor stage (suprasellar extension) was the strongest predictor of outcome (p < 0.0002). The preoperative GH level, preoperative SM-C level, and tumor grade were also significant univariate predictors (p = 0.001, p = 0.01, and p < 0.01, respectively). Even when other significant outcome predictors were controlled, tumor stage and grade remained significant independent predictors, with tumor stage being the strongest outcome predictor (p = 0.05). However, the preoperative GH level was not significant in determining outcome (p = 0.058) when other significant outcome variables were controlled.
The probability of long-term failure of surgical therapy is expressed as: e~/1 + e x, where e, the base of the natural system of logarithms, is approximately 2.7 1828 and x is the function of the preoperative GH and SM-C levels, tumor grade and stage, and their respective intercepts and parameter estimates. Tumor Grade~ and Grade2 and tumor Stageo and StageABc are all binary variables assuming one of two possible values, 1 or 0; the coding strategy is set as yes = 1 and no = 0. For example, if a Grade I tumor is present, then Grade~ = 1 and Grade2 = 0, so on through all the models. Based on our clinical hypotheses and the results of univariate analysis, we explored four models. These four different conditions determine x as follows (Table 4) .
Model 1.
Using the preoperative serum basal GH level and tumor grade as predictors of outcome, the value for x is derived using the intercept and parameter estimates for the preoperative GH level and tumor grade in the regression equation.
Model 2.
Using the preoperative serum basal GH level and tumor stage as predictors of outcome, the value for x is derived using the intercept and parameter estimates for the preoperative GH level and tumor stage.
Model 3.
Using the preoperative SM-C level as a predictor of outcome, the value for x is derived using the intercept and parameter estimates for the preoperative SM-C level. Due to the small sample size of the patients for whom the preoperative SM-C level was determined, we were unable to break down the analysis according to tumor stage and grade as we have done for the preoperative GH level where the sample size was much larger.
Model 4.
Using the preoperative serum basal GH level and tumor stage and tumor grade as predictors of outcome, the value for x is derived using the intercept and parameter estimates for the preoperative GH level and tumor stage and grade.
One limitation of a regression data set is failure to collect information about all potentially important re-gressors. In comparing our findings with other large surgical series, similar variables, including preoperative GH level, 6'1~176 preoperative SM-C level, tumor stage, 37'4L4s and tumor grade, 4863 were significant determinants of outcome. Although these series did not use logistic regression analysis, it is unlikely that we have omitted significant regressors. One exception may be patients who received preoperative treatment of any kind; we did not include these patients in our regression model since there were only four patients with prior medical treatment and 11 patients who received disparate forms of radiotherapy. It has been reported that patients treated initially with transsphenoidal microsurgery fare better than those who received prior alternative treatment. Although we are unable to comment definitively on this subset of patients, our results in these patients are consistent with those of others. 5' 10.48.53 Another factor to be considered in the use of regression analysis is that the models are most reliable within the range for which actual data are available. This caveat should be borne in mind when deriving information from a regression curve.
Failures of Surgical Treatment
Eighteen patients in this series did not meet the criteria for surgical control of acromegaly. They were nine women and nine men, ranging in age from 20 to 72 years (mean 40.9 _+ 11.9 years). The average age of patients whose acromegaly was controlled by surgery (46.1 _+ 12.5 years) was higher than this group, but this was not statistically significant (p = 0.1). However, other evidence suggests that younger patients do tend to have more aggressive tumors. 39
Endocrinological Studies. Preoperative basal GH levels were available in all I8 patients in the surgical failure group and ranged from 21 to 161 ug/liter (mean 68.4 _+ 9.8 ug/liter). The mean preoperative GH level was significantly lower in the 82 patients successfully treated by surgery (34.7 _+ 3.5 ~g/liter, p = 0.04) ( Table  5) . A similar observation has been made by others. 6, I 0.23,48 Preoperative SM-C levels, available in 29 patients, were significantly higher in the surgical failure group (five patients, mean 10.4 _+ 5.1 U/ml) than in the surgically controlled group (24 patients, mean 4.1 + 3.4 U/ml, p < 0.05). This finding is supported by the higher mean serum basal preoperative GH level in the surgical failure group (Table 5) .
Preoperative prolactin values were available for 14 patients in the surgical failure group and ranged from 5 to 345 tzg/liter (mean 60.5 _+ 90.5 ~g/liter). This difference was not statistically significant when compared with the mean prolactin level (31.2 _+ 37.1 ug/ liter) in the 51 patients with surgically controlled acromegaly (Table 5) .
Tumor Stage and Grade. The extent of suprasellar extension was significantly different among surgical failures and successes (p = 0.009). Table 6 shows the breakdown of these tumor parameters between patients whose acromegaly was and was not controlled by surgery. 
G. T. Tindall, et al.
Adjuvant Therapy
The choice of adjuvant therapy remains controversial. Patients in this series whose acromegaly was not controlled by surgery were treated in several ways. Postoperative radiotherapy alone was carried out in five patients. Bromocriptine (Padodel) therapy alone was prescribed in six patients. Seven patients received both. Table 7 details the postoperative GH and SM-C levels in four groups of patients classified by treatment modality.
Discussion
It is currently accepted that transsphenoidal microsurgical adenomectomy is a safe and effective treatment for GH-secreting tumors in acromegaly. For most patients it is the preferred choice of therapy. However, some patients will not be cured by this operation alone. Recognizing the determinants of surgical failure is an 0.4to6.9 0.2to 12.0 2.9 _+ 2.4 1.7 _+ 2.2 6 30 * Abbreviations: GH = growth hormone; SM-C = somatomedin C; SEM = standard error of the mean.
essential step in ensuring the most favorable surgical outcome. We have analyzed our surgical outcomes to determine which factors were associated with failure and, further, to derive estimates for the probability of surgical failure in an effort to guide future decisionmaking.
Surgical Outcome
Overall, 88% of our 103 patients with acromegaly had a postoperative GH level of less than 5 ug/liter at long-term follow-up evaluation. This outcome compares favorably with a recent review in which 60% of 1360 patients with acromegaly treated by transsphenoidal surgery achieved a reduction in postoperative GH levels to less than 5 ug/liter. 34 Although tumor stage was the strongest predictor of surgical failure, a moderate degree of suprasellar extension does not preclude successful tumor resection. As the sellar portion of the tumor is removed, more rostral portions sink into the field, allowing further resection. This was borne out by the 40% control rate in Stage C and D tumors. However, as evidenced by the uniformly poor results in Stage E tumors, lateral extension into the cavernous sinus makes complete surgical resection by the transsphenoidal approach an unrealistic goal.
Tumor grade and stage are readily estimated by current imaging techniques and were significant predictors in our regression models. Therefore, we urge these classifications in other series so that these models may be tested. The preoperative SM-C level was a significant predictor of surgical outcome (p < 0.05) in our logistic regression model. This finding increases the utility of SM-C levels in patients with acromegaly, especially as the SM-C levels are significantly correlated with preoperative GH levels (r = 0.45, p = 0.009) and are a more integrated index of GH activity. Therefore, GH dynamic testing may be less of a necessity for evaluating surgical series.
Some reports suggest that previous treatment with radiotherapy or craniotomy 4'~c'4~~4~~ adversely affects the success of subsequent transsphenoidal surgery. Our disease control rates were higher in patients who did not receive prior treatment (82.4%) compared with patients who received bromocriptine therapy (75%) and those who underwent radiotherapy (63.6%). However, our sample sizes were relatively small and comparisons may be unreliable.
Adjuvant Therapy
Choosing adjuvant therapy for patients whose acromegaly was not controlled by surgery alone remains bothersome, and we have been burdened by the same dilemmas facing others. In this series, we treated five of 18 patients with radiotherapy, six with bromocriptine administration, and seven with both. One patient receiving radiation and bromocriptine therapies also received octreotide. Assignments to adjuvant treatment groups were not random or matched in any way. Treatment options were individualized and were based in part on consultation with other specialists and the patients.
Regarding radiotherapy, both conventional and heavy-particle (proton-beam) irradiation have been used as primary and adjuvant therapy for acromegaly. In conventional radiation therapy, usually 40 to 50 Gy is administered for 4 to 6 weeks. In most patients GH levels begin to decline during the 1st year after treatment and continue to decrease thereafter. The reduction in GH levels is more rapid with proton-beam radiation therapy, but local complications are more common. One study suggested that long-term reductions in GH levels are similar with both conventional and proton-beam radiotherapy but recommended conventional radiotherapy in preference to proton-beam radiotherapy in view of the tendency to more serious side effects with the latter. 38 With both forms of radiation therapy, tumor growth is arrested and most adenomas shrink. 18,> A common side effect of pituitary radiotherapy is trophic hormone failure, which occurs in 40% to 50% of patients after 10 years. 29 Although bromocriptine administration may be used as primary or adjuvant therapy for acromegaly, we have used it only as postoperative adjuvant therapy for six of the 18 surgical failures. Doses of up to 20 rag/day are usually required. 62 Bromocriptine suppresses GH hypersecretion in 20% to 30% of patients with acromegaly and shrinks GH-secreting pituitary adenomas in a minority of cases. 62 These modest benefits together with its side effects at higher doses make bromocriptine therapy a marginally attractive adjuvant treatment.
Octreotide, the long-acting somatostatin analog, is a viable alternative medical onion for suppression of GH hypersecretion in active acromegaly. 9"31' 32' 4358 In particular, preoperative administration of octreotide results in significant tumor shrinkage and normalizes GH levels before surgery, s,33`ez Octreotide is not eytotoxic and tumor regrowth occurs after its withdrawal, as with bromocriptine. 7-8 Substantial clinical improvement also occurs during octreotide therapy? ~ However, it is more expensive than bromocriptine and it has to be given by subcutaneous injection (two to three times daily in the average patient).
Ideally, a controlled study of the separate or adjuvant use of the three available treatments (transsphenoidal surgery, irradiation, and medical therapy) could determine the best management options for patients who do not respond to transsphenoidal surgery alone. Given the difficulties in mounting such a study and the followup monitoring required to properly assess outcome, the considered judgment of the clinician combined with less formal studies may have to suffice for the present.
